Although the hematological evaluation might have lacked specific (clinical or neurophysiological) neurological scales to properly grade the neuropathic response to ibrutinib, these preliminary data are promising and indicate that ibrutinib does not worsen neuropathy and may improve it, thus offering a potential therapeutic option in IgM paraproteinemic polyneuropathies [93, 96]. Here, CD40LG is linked to neuropathy.